Recursion Pharmaceuticals (RXRX) Rises Higher Than Market: Key FactsZacks Investment Research • 07/17/25
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the StockZacks Investment Research • 07/17/25
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia ProgramZacks Investment Research • 07/09/25
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?Zacks Investment Research • 07/02/25
MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and AccuracyGlobeNewsWire • 06/06/25
Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/04/25
RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?Zacks Investment Research • 05/27/25
Recursion Pharmaceuticals Plunges 22% in May: How to Play the StockZacks Investment Research • 05/15/25
Should You Buy This Beaten-Down Artificial Intelligence (AI) Stock on the Dip?The Motley Fool • 05/12/25
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/05/25
Recursion Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/05/25
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp BurdenGlobeNewsWire • 05/04/25